Neuralgia News and Research

RSS

Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

AANS, CNS urge Congress to restore Medicare payments for stereotactic radiosurgery

he American Association of Neurological Surgeons and Congress of Neurological Surgeons are urging Congress to restore Medicare hospital outpatient payment rates for Cobalt-60-based stereotactic radiosurgery to those in place prior to the enactment of the American Taxpayer Relief Act.

21 Mar 2013

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.

14 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Depomed third quarter 2012 revenue increases to $33.3 million

Depomed, Inc. today reported financial results for the quarter and nine months ended September 30, 2012.

5 Nov 2012

Neuros Medical honored as most promising startup

Neuros Medical, Inc., a medical device company, was presented the 2012 Gold Electrode Award for Most Promising Startup at the Neurotech Leaders Forum conference in San Francisco. The award is given by Neurotech Reports, and highlights a company in the neuromodulation industry that holds the most promise.

29 Oct 2012

Population Health Management discusses latest information on shingles and PHN

Shingles, a reactivation of the herpes zoster (chickenpox) virus affects nearly 1 in 3 Americans. About 1 million cases are diagnosed each year, with some patients suffering excruciating pain and itching due to post-herpetic neuralgia (PHN), a complication of the viral infection that can last for years despite treatment.

26 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.

31 Jul 2012

Treatments for peripheral neuropathic pain compared

The first study to compare the 8% capsaicin patch with pregabalin as a treatment for peripheral neuropathic pain begins, with enrolment of the first patient.

31 Jul 2012

Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.

24 Jul 2012

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.